Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VEE VLP Vaccine in Healthy Adults
NCT03776994Phase 1Unknown
- Sponsor
- SRI International
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of VEE VLP vaccine in Venezuelan equine encephalitis (VEE) (6 arms), sponsored by SRI International. Primary endpoints: Number of subjects reporting solicited local adverse events at 44 weeks, Number of subjects reporting solicited systemic adverse events at 44 weeks and 5 more. Status: unknown.
02
Drugs
VEE VLP vaccine
03
Conditions
Venezuelan equine encephalitis (VEE)
Beyond the preview
Go deeper on NCT03776994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776994.